Go Back
Go Back

Day 1

16 D. Papaioannou - D. Classic high-risk histology vs molecular risk - do T4, ​​12 nodes, LVI and poor differentiation still drive the decision or does ctDNA override them?

16 D. Papaioannou - D. Classic high-risk histology vs molecu...

17 G. Papaxoinis - Case: Metastatic dMMR CRC: from missed adjuvant IO to frontline

17 G. Papaxoinis - Case: Metastatic dMMR CRC: from missed ad...

18 B. Brenner - A. COMMIT and frontline IO in dMMR mCRC - dual IO vs mono IO vs chemo-IO: how to choose in 2026.

18 B. Brenner - A. COMMIT and frontline IO in dMMR mCRC - du...

19 K. Kamposioras - B. ATOMIC trial - adjuvant atezolizumab in stage III dMMR and implications for those who missed it.

19 K. Kamposioras - B. ATOMIC trial - adjuvant atezolizumab...

20 S.I. Chrysoglou - C. Response assessment in dMMR mCRC - RECIST limits with IO, pseudoprogression patterns.

20 S.I. Chrysoglou - C. Response assessment in dMMR mCRC - R...

21J. Marquardt - D. Gastroenterologist immune-related adverse events - IO colitis diagnosis, management and when toxicity forces IO discontinuation.

21J. Marquardt - D. Gastroenterologist immune-related advers...

22 K. Pavlou - Part 1: Pathologist with molecular insights.

22 K. Pavlou - Part 1: Pathologist with molecular insights.

23 V. Sivanathan - Part 2: Endoscopic features and management.

23 V. Sivanathan - Part 2: Endoscopic features and managemen...

24 Th. Tsirlis - B. Liver resectability in BRAF mCRC - upfront vs response-guided surgery, molecular profile and surgical intent.

24 Th. Tsirlis - B. Liver resectability in BRAF mCRC - upfro...

25 E.S. Tripodaki - A. BREAKWATER - encorafenib + cetuximab + FOLFIRI as 1st line: evidence and patient selection.

25 E.S. Tripodaki - A. BREAKWATER - encorafenib + cetuximab...

26 G. Nintos - Non-V600E BRAF mutations in mCRC - how to treat.

26 G. Nintos - Non-V600E BRAF mutations in mCRC - how to tre...

27 M. Vogiatzis - C. PET-CT in BRAF mCRC - FDG avidity, response assessment beyond CT, surgical timing.

27 M. Vogiatzis - C. PET-CT in BRAF mCRC - FDG avidity, resp...

28 M. Moehler - B. Regorafenib, TAS-102 and beyond - selection, sequencing, dose optimization, ctDNA-guided EGFR rechallenge.

28 M. Moehler - B. Regorafenib, TAS-102 and beyond - selecti...

29 S. Grigoriadis - C. Locoregional options in later lines - HAI, ablation, SBRT as adjuncts when oligoprogression occurs.

29 S. Grigoriadis - C. Locoregional options in later lines -...

30 M. Avgoustidou - D. Goals-of-care in advanced lines - presenting options without false hope, QoL trade-offs, when to shift focus.

30 M. Avgoustidou - D. Goals-of-care in advanced lines - pre...